Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 5/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 5/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 5/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 5/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 5/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 5/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6021110 | 1.00 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1557957 | 1.00 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5059534 | 0.87 | GRIN2D (0.77) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8828056 | 0.84 | GRIN2D (0.72) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5059538 | 0.82 | GRIN2D (0.69) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9749886 | 0.82 | GRIN2D (0.69) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15959451 | 0.81 | MAPT (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1999794 | 0.81 | MAPT (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28519158 | 0.81 | GRIN2D (0.68) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9676414 | 0.81 | GRIN2D (0.68) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 649 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372326-A1 | Pain Medicine Combination and Uses Thereof | Mindlab LLC | 2023-11-23 | — | — | US | claimed |
| US-20220211677-A1 | MEDICINE COMBINATIONS AND TREATMENT OF RESTLESS LEG SYNDROME | Mindlab, LLC | 2022-07-07 | — | — | US | claimed |
| US-10570522-B2 | Etching solution for copper or copper alloy | ENTEGRIS, INC. (US) | 2020-02-25 | — | — | US | claimed |
| EP-2964022-B1 | PAIN MEDICINE COMBINATION AND USES THEREOF | Mindlab LLC (US) | 2019-11-06 | — | — | EP | claimed |
| CN-106435587-B | For copper or the etching solution of copper alloy | 恩特格里斯公司 | 2019-10-01 | — | — | CN | claimed |
| EP-3512600-A1 | MEDICINE COMBINATIONS AND TREATMENT OF RESTLESS LEG SYNDROME | Mindlab LLC (US) | 2019-07-24 | — | — | EP | claimed |
| WO-2018052926-A1 | MEDICINE COMBINATIONS AND TREATMENT OF RESTLESS LEG SYNDROME | Mindlab LLC (US) | 2018-03-22 | — | — | WO | claimed |
| US-20170333369-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2017-11-23 | — | — | US | claimed |
| US-9808460-B2 | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2017-11-07 | — | — | US | claimed |
| CN-106435587-A | ETCHING SOLUTION FOR COPPER OR COPPER ALLOY | 恩特格里斯公司 | 2017-02-22 | — | — | CN | claimed |
| US-5399693-A | Substituted piperazine-2-carboxylic acids and derivatives thereof | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-03-21 | — | — | US | claimed |
| EP-0533832-A4 | TREATMENT OF MOOD DISORDERS WITH FUNCTIONAL ANTAGONISTS OF THE GLYCINE/NMDA RECEPTOR COMPLEX | US COMMERCE (US) | 1993-04-28 | — | — | EP | claimed |
| EP-0533832-A1 | TREATMENT OF MOOD DISORDERS WITH FUNCTIONAL ANTAGONISTS OF THE GLYCINE/NMDA RECEPTOR COMPLEX | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1993-03-31 | — | — | EP | claimed |
| EP-0159889-B1 | 4-SUBSTITUTED PIPERAZINE-2-CARBOXYLIC ACIDS PROCESS AND PHARMACEUTICAL COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 1992-09-30 | — | — | EP | claimed |
| WO-1991019493-A1 | TREATMENT OF MOOD DISORDERS WITH FUNCTIONAL ANTAGONISTS OF THE GLYCINE/NMDA RECEPTOR COMPLEX | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1991-12-26 | — | — | WO | claimed |
| EP-0432994-A2 | Excitatory amino acid antagonists as anti-emetic drugs | Olney, John William (US) | 1991-06-19 | — | — | EP | claimed |
| EP-0371085-A4 | DEXTROMETHORPHAN POTENTIATOR FOR ANTICONVULSANT COMPOSITION AND METHOD | — | 1990-10-24 | — | — | EP | claimed |
| EP-0371085-A1 | DEXTROMETHORPHAN POTENTIATOR FOR ANTICONVULSANT COMPOSITION AND METHOD | PONTECORVO, Michael (US) | 1990-06-06 | — | — | EP | claimed |
| WO-1989005641-A1 | DEXTROMETHORPHAN POTENTIATOR FOR ANTICONVULSANT COMPOSITION AND METHOD | PONTECORVO MICHAEL J (US) | 1989-06-29 | — | — | WO | claimed |
| EP-0159889-A2 | 4-Substituted piperazine-2-carboxylic acids process and pharmaceutical compositions | BTG INTERNATIONAL LIMITED (GB) | 1985-10-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333369-A1 | Pharmaceutical Combination | GRIN3A, GRIN2B, GRIN2C | GRIN2D 13/4885GRIN3B 4/4885GRIN1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.